.png){kind=icon}
Access comprehensive services for antimicrobial development, including a wide range of validated in vivo models complimented by full in vitro support. Have a custom need? We are happy to collaborate to develop and validate bespoke models tailored to your criteria. We also offer stand-alone in vitro assays to investigate efficacy against a wide range of bacterial and fungal pathogens. With expertise in efficacy models, pharmacokinetic (PK) models, and safety models, you can count on quality studies with accelerated data delivery.
In vivo models of infection:
- アスペルギルス肺感染症、マウス
- カンジダ・アルビカンスによる敗血症、マウス
- B 型肝炎ウイルス（HBV）、マウス
- AAV-HBV、HBV/HDV、HBV 変異型
- HBV に感染したヒト肝臓キメラマウス モデル（PXB® マウス）
- インフルエンザ（H1N1）、マウス / フェレット
- メチシリン耐性黄色ブドウ球菌（MRSA）好中球減少性大腿部感染症 PK/PD モデル、ラット
- 緑膿菌による肺感染症、マウス
- 呼吸器合胞体ウイルス（RSV）による肺感染症、マウス
- 肺炎連鎖球菌による肺感染症、マウス
- Streptococcus pneumoniae sepsis model, mouse
In vivo study support services:
- Preparation of bacterial/viral/fungal infective doses, including agar bead prep for bacterial and fungal respiratory models
- Organ/tissue bioburden counts
- Viral titre assays (CPE assay, Plaque assay)
- Bacteriophage plaque assays
In vitro antimicrobial efficacy:
- In vitro Minimum Inhibitory Concentration (MIC) assays
- Aerobic/anaerobic bacteria and fungal pathogens (Hazard class 2)
- Antibiotic resistance/susceptibility testing
Non-animal model for assessment of acute toxicity and antimicrobial efficacy:
- Galleria mellonella wax moth larva model - TruLarvTM
